Alumis Inc. (ALMS) — 8-K Filings

8-K Filings (18)

• Alumis Inc. Files 8-K with Exhibits — Mar 30, 2026 Risk: low
  Alumis Inc. filed an 8-K on March 30, 2026, reporting other events and financial statements. The filing includes various exhibits, such as graphics, indicating
• Alumis Inc. Files Form 8-K — Sep 3, 2025 Risk: low
  Alumis Inc. reported on September 3, 2025, that its Common Stock, trading under the symbol ALMS on The Nasdaq Global Select Market, is subject to a Form 8-K fil
• Alumis Inc. Files 8-K on Shareholder Vote Matters — Aug 4, 2025 Risk: low
  Alumis Inc. filed an 8-K on August 4, 2025, reporting on matters submitted to a vote of security holders as of July 30, 2025. The company, formerly known as Esk
• Alumis Inc. Completes Acquisition, Announces Leadership Changes — May 21, 2025 Risk: medium
  Alumis Inc. announced on May 21, 2025, the completion of its acquisition of Esker Therapeutics, Inc. The filing also details the departure of certain officers a
• Alumis Inc. Files 8-K on Shareholder Vote Matters — May 19, 2025 Risk: low
  Alumis Inc. filed an 8-K on May 19, 2025, reporting on matters submitted to a vote of security holders on May 13, 2025. The company, formerly known as Esker The
• Alumis Inc. Enters Material Definitive Agreement — Apr 21, 2025 Risk: medium
  Alumis Inc. announced on April 20, 2025, that it entered into a material definitive agreement. The company, formerly known as Esker Therapeutics, Inc., is incor
• Alumis Inc. Files 8-K: Other Events & Financials — Mar 25, 2025 Risk: low
  Alumis Inc. filed an 8-K on March 25, 2025, reporting other events and financial statements. The company, formerly Esker Therapeutics, Inc., is incorporated in
• Alumis Inc. Files 8-K, Formerly Esker Therapeutics — Mar 18, 2025 Risk: low
  On March 18, 2025, Alumis Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 280 East Grand Avenue, South S
• Alumis Inc. Files 8-K: Other Events & Financials — Mar 10, 2025 Risk: low
  Alumis Inc. filed an 8-K on March 10, 2025, reporting other events and financial statements/exhibits as of March 8, 2025. The company, formerly Esker Therapeuti
• Alumis Inc. Files 8-K: Regulation FD & Financials — Mar 4, 2025 Risk: low
  Alumis Inc. filed an 8-K on March 4, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly Esker Therapeuti
• Alumis Inc. Reports Board and Executive Compensation Changes — Feb 21, 2025 Risk: medium
  Alumis Inc. announced on February 18, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certa
• Alumis Inc. Enters Material Definitive Agreement — Feb 6, 2025 Risk: medium
  Alumis Inc. announced on February 6, 2025, that it entered into a material definitive agreement. The company, formerly Esker Therapeutics, Inc., is involved in
• XOMA to Acquire Alumis Inc. — Nov 25, 2024 Risk: medium
  Alumis Inc. announced on November 22, 2024, that it has entered into a definitive agreement to be acquired by XOMA Corporation. The transaction is expected to c
• Alumis Inc. Files 8-K on Financials — Nov 13, 2024 Risk: low
  Alumis Inc. filed an 8-K on November 13, 2024, reporting on its results of operations and financial condition, and including financial statements and exhibits.
• Alumis Inc. Files 8-K on Operations and Financials — Aug 13, 2024 Risk: low
  Alumis Inc. filed an 8-K on August 13, 2024, reporting on its results of operations and financial condition. The filing also includes financial statements and e
• XOMA to Acquire Alumis Inc. — Jul 18, 2024 Risk: medium
  Alumis Inc. announced on July 17, 2024, that it has entered into a definitive agreement to be acquired by XOMA Corporation. The transaction is expected to close
• Alumis Inc. Files 8-K for Equity Sales and Financials — Jul 3, 2024 Risk: medium
  On June 27, 2024, Alumis Inc. entered into a Material Definitive Agreement related to unregistered sales of equity securities. The filing also includes financia
• Alumis Inc. Files 8-K for Bylaws and Financials — Jul 1, 2024 Risk: low
  Alumis Inc. filed an 8-K on July 1, 2024, reporting amendments to its Articles of Incorporation or Bylaws and filing financial statements and exhibits. The comp

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX